CLINICAL REPORTSCutaneous squamous cell carcinoma responding serially to single-agent cetuximabSuen, Jacqueline K.a; Bressler, Lindab; Shord, Stacy S.b; Warso, Michaelc; Villano, John LeeaAuthor Information Departments of aMedicine, Section of Hematology and Oncology bPharmacy Practice cSurgical Oncology, University of Illinois at Chicago, Chicago, Illinois, USA Correspondence to John Lee Villano, Departments of Medicine, Section of Hematology and Oncology, University of Illinois at Chicago, Chicago, IL 60612, USA Tel: +1 312 996 6768; e-mail: [email protected] Received 12 December 2006 accepted 12 January 2007 Anti-Cancer Drugs: August 2007 - Volume 18 - Issue 7 - p 827-829 doi: 10.1097/CAD.0b013e32809ef9e0 Buy Metrics Abstract Cetuximab (Erbitux®) is a recombinant, chimeric monoclonal antibody that binds with high affinity to the extracellular ligand-binding domain of human epidermal growth factor receptor. We report a case of repeated responses to cetuximab in a patient with nonresectable squamous cell skin cancer having strong human epidermal growth factor receptor expression. Nonmelanoma skin cancer is the most common cancer in the US, with more than 1 million new cases detected annually, of which 20–25% are squamous cell carcinomas. Although most primary cutaneous squamous cell carcinomas have a high clinical cure rate and are easily treated, the small subset of cancers that recur or metastasize has a poor prognosis, and accounts for approximately 2000 deaths per year. Treatment with cetuximab should be considered for human epidermal growth factor receptor expressing tumors in a palliative setting. © 2007 Lippincott Williams & Wilkins, Inc.